Precigen Inc Cash Flow Conversion Efficiency
Precigen Inc cash flow conversion efficiency. Based on the latest financial reports, Precigen Inc (PGEN) has a cash flow conversion efficiency ratio of -0.409x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-17.81 Million) by net assets ($43.58 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Precigen Inc (2011–2025)
Cash flow conversion efficiency of Precigen Inc from 2011 to 2025. This chart illustrates how Precigen Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Precigen Inc stock price for real-time trading data and today's change.
Precigen Inc Cash Flow Conversion Ratio Explained
Precigen Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Precigen Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Precigen Inc ranked by their cash flow conversion efficiency. Also see market value of Precigen Inc for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
P/F Bakkafrost
F:6BF
|
0.040x |
|
Inari Amertron Bhd
KLSE:0166
|
0.027x |
|
Enerflex Ltd.
NYSE:EFXT
|
0.028x |
|
People.Cn Co Ltd
SHG:603000
|
0.020x |
|
BitVentures Limited
NASDAQ:BVC
|
N/A |
|
GN Store Nord
CO:GN
|
0.113x |
|
China Baoan Group Co Ltd
SHE:000009
|
0.010x |
|
KANSAI PAINT SPON.ADR/1/2
F:KAP0
|
N/A |
Annual Cash Flow Conversion Efficiency for Precigen Inc (2011–2025)
The table below shows the annual cash flow conversion efficiency of Precigen Inc from 2011 to 2025. Review PGEN FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $20.91 Million | $-87.83 Million | -4.200x | -137.28% |
| 2024-12-31 | $38.51 Million | $-68.17 Million | -1.770x | -213.40% |
| 2023-12-31 | $118.50 Million | $-66.93 Million | -0.565x | -9.64% |
| 2022-12-31 | $126.26 Million | $-65.05 Million | -0.515x | +0.84% |
| 2021-12-31 | $107.35 Million | $-55.77 Million | -0.520x | +54.69% |
| 2020-12-31 | $67.17 Million | $-77.02 Million | -1.147x | -6.75% |
| 2019-12-31 | $71.71 Million | $-77.02 Million | -1.074x | -227.40% |
| 2018-12-31 | $378.72 Million | $-124.24 Million | -0.328x | -72.17% |
| 2017-12-31 | $546.54 Million | $-104.14 Million | -0.191x | -93.77% |
| 2016-12-31 | $569.25 Million | $-55.98 Million | -0.098x | -294.32% |
| 2015-12-31 | $704.89 Million | $35.67 Million | 0.051x | +204.30% |
| 2014-12-31 | $409.29 Million | $-19.86 Million | -0.049x | +65.53% |
| 2013-12-31 | $381.34 Million | $-53.68 Million | -0.141x | -173.57% |
| 2012-12-31 | $-321.55 Million | $-61.53 Million | 0.191x | -48.22% |
| 2011-12-31 | $-221.26 Million | $-81.76 Million | 0.370x | -- |
About Precigen Inc
Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors… Read more